Drug addiction-stopping formulation and preparation thereof

Abstract

The invention relates to a drug rehabilitation preparation and method for preparation, wherein the preparation comprises predetermined amount of tetrodontoxin monomer as the main effective composition, right amount of auxiliary material carrier, function modifier and tetrodontoxin derivative as the stabilizer, the acidic dissolvent carrier is selected from acetic acid / sodium acetate, or citric acid / sodium citrate, or citric acid / disodium hydrogen phosphate, the function modifier is at least one selected from trichlorbutanolum, benzoic alcohol and lignocaine hydrochloride.

Description

technical field [0001] The invention relates to a medicinal preparation containing natural organic active ingredients, and uses marine biological toxin nerve center sodium ion channel blockers as ice drugs [amphetamine (amphetamine), methamphetamine (ice drug), 3, 4 subtypes] Methyldioxymethamphetamine (MDMA, commonly known as: ecstasy, also known as XTC, Smurfs, Adam, love him to die, out of body, etc.)], heroin and other opioids (heroin, morphine, codeine, doloretine , dihydroetorphine, opium, methadone, etc.), cannabis (including cannabis resin, cannabis oil, "Mary Warner" (called "Ganja" in India, "Kib" in North Africa, "Mary Warner") "Bhang" in South Africa, "Dagga" in South Africa), and "Hashish", which is processed from the top flowers and part of the leaves of the female cannabis plant] The preparation and application of drug detoxification preparations, especially involving tetrodotoxin in an accurate amount Monomer (purity > 99%) is used as main active ingredient...

AI Technical Summary

Problems solved by technology

[0011] The above inventions have played a positive role in promoting tetrodotoxin into clinical application research, but there are still unresolved key technical problems in terms of the accurate measurement of active ingredients in its preparations and the stability of effective doses for clinical use.

Wherein the publication number is W095 / 24903 patent disclosed detoxification dose and the poisoning dose of tetrodotoxin is close, example experimenter presents the poisoning symptom (tongue, mouth, lip complete numbness that part also includes upper and lower extremities) that tetrodotoxin induces. Numbness); in the patent No. 9611549454.5, the therapeutic dose of tetrodotoxin is 0.5-10.0 μg / 1-20ml, and the dose used in the example is injected intramuscularly or intravenously once a day, 20 μg each time, but it is obtained by the extraction process used Tetrodotoxin is not a pure product, but a mixture containing at least 2 to 3 derivatives. There are following problems in clinical use: the dose of tetrodotoxin cannot be accurately controlled, and the content or proportion of unseparated derivatives in the preparation cannot be determined , which will lead to uncertainty in the content of tetrodotoxin in the preparation, which not only affects the therapeutic effect, but also cannot guarantee the safety of medication; The dose-response needs to be further verified

However, how to ensure the accurate measurement of the main active ingredients of tetrodotoxin to ensure the safety of tetrodotoxin in clinical use, and the stability of tetrodotoxin as an active ingredient in the preservation process after the formulation of preparations have not been commented or resolved.

Images